ketoconazole has been researched along with glycine in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Retico, A; Simonetti, N; Villa, A | 1 |
Aoki, Y; Arisawa, M; Kondoh, M; Nakamura, Y; Nakayama, N; Yoshihara, F | 1 |
Bacic, A; Callaghan, JM; Currie, G; Ferguson, K; McConville, MJ; McFadden, GI; Naderer, T; Spurck, T; Tull, D; Vince, JE | 1 |
Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X | 1 |
Fan, B; Ke, A; Le, K; Prakash, C; Yang, H | 1 |
1 trial(s) available for ketoconazole and glycine
Article | Year |
---|---|
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Glycine; Humans; Ketoconazole; Male; Middle Aged; Models, Biological; Neoplasms; Proteasome Inhibitors; Rifampin | 2018 |
7 other study(ies) available for ketoconazole and glycine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Action of the ketoconazole-alkylaminoethylglycine combination on Candida albicans.
Topics: Candida albicans; Cell Membrane Permeability; Drug Combinations; Glycine; Ketoconazole | 1989 |
Ro 09-1470 is a selective inhibitor of P-450 lanosterol C-14 demethylase of fungi.
Topics: Animals; Antifungal Agents; Carbon Monoxide; Cholesterol; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluconazole; Fungal Proteins; Glycine; Heme; Ketoconazole; Liver; Male; Microsomes, Liver; Oxidoreductases; Pyrans; Rats; Rats, Sprague-Dawley; Saccharomyces cerevisiae; Sensitivity and Specificity; Sterol 14-Demethylase | 1993 |
SMP-1, a member of a new family of small myristoylated proteins in kinetoplastid parasites, is targeted to the flagellum membrane in Leishmania.
Topics: Amino Acid Sequence; Animals; Cell Membrane; Cloning, Molecular; Cysteine; Cytoskeleton; Detergents; Epitopes; Fatty Acids; Fatty Acids, Monounsaturated; Flagella; Glycine; Immunoblotting; Ketoconazole; Kinetoplastida; Leishmania major; Lipid Metabolism; Membrane Proteins; Microscopy, Electron; Microscopy, Fluorescence; Molecular Sequence Data; Myristic Acid; Octoxynol; Palmitic Acid; Phylogeny; Polyethylene Glycols; Protein Structure, Tertiary; Sequence Homology, Amino Acid; Sphingolipids; Temperature; Tubulin | 2004 |
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Fluconazole; Glycine; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Leukemia, Myeloid, Acute; Male; Microsomes, Liver; Models, Biological; Pyridines; Rifampin | 2020 |